Global Herpes Zoster Infection Treatment Market to reach USD XX Million by 2027.Global Herpes Zoster Infection Treatment Market is expected to grow by USD XX Million in 2020 and is accelerated to grow at CAGR of almost 4.1% over the forecast period 2021-2027.
Herpes Zoster, also known as shingles, is a viral infection that causes painful rashes on skin. Herpes Zoster is caused by the Varicella zoster virus, it is the same that causes Chicken pox as well. After the person has had chicken pox, the virus lies dormant in certain nerves for years and its reactivation causes Herpes Zoster Infection. Although, the infection is incurable, vaccines are available to prevent shingles and long-lasting nerve pain that sometimes develops. Herpes Zoster can affect anybody with weak immune system; it is more likely to be found in people aged over 50 years, HIV and cancer patients. The rising prevalence rate of shingles in older population and predominance of effective antibodies are the prime reasons driving the growth of herpes zoster treatment market. The herpes infection rate and increasing elderly population are fueling the overall demand of the market. For instance, according to the National Foundation for Infectious Diseases, about 98% of the US adults have had chicken pox and are at risk of shingles. Almost 1 out of 3 people in the US will develop shingles during their lifetime.
Furthermore, there is substantial increase in research and development activities. The market is growing due to the availability of effective vaccines and drugs to keep the patient healthier and provide treatment without hospitalization. On the flip side, costly antibodies are restraining vaccination drive in developing economies. Inadequate scope of the prevention, improper reimbursement policies and lack of healthcare guidance etc. are hampering the growth of the market.
North America accounts for majority of the shares in Herpes Zoster Infection Treatment Market among all regional markets, due to increase in the government support for various vaccination and awareness programs and funds provided by them. Apart from this, Asia pacific, Middle East and Africa will emerge as fastest growing countries due to increasing prevalence of the herpes zoster disease.


Major market player included in this report are:
Bausch Health Companies Inc.
Cipla Inc.
Eli Lilly and Co.
Gilead Sciences Inc.
GlaxoSmithKline Plc
Maruho Co. Ltd.
Merck & Co. Inc.
Mylan NV
Novartis AG
Teva Pharmaceutical Industries Ltd


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug type:
Antivirals
Analgesic
Non-Steroidal Anti-inflammatory drug
others
By Vaccination type:
Monovalent
Combination
By End User:
Hospitals and clinics
Diagnostic centers
others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Herpes Zoster Infection Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors